ADDED
They appear in several places throughout this report and include statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the markets in which we operate.
Risks Related to Intellectual Property, Cybersecurity, Information Technology and Data Management Practices interruptions, defects, failures or vulnerabilities in our technology systems or those of third-party providers; cybersecurity incidents, data breaches or misuse of artificial intelligence technologies that could disrupt operations or expose sensitive information; our ability to protect and enforce intellectual property rights; and risks associated with our use of open-source software.
Legal and Regulatory Risks Related to Our Business our operations within highly regulated aviation, healthcare and transplant environments, including evolving federal, state and local laws and regulations; the impact of any litigation or regulatory investigations that we may be subject to; our ability to comply with privacy, data protection, consumer protection and security laws; and the expansion of environmental regulations.
Other Risks our ability to remediate any material weaknesses or maintain effective internal controls over financial reporting; our ability to maintain effective disclosure controls and procedures; and the other factors described elsewhere in this Annual Report, included under the headings Risk Factors, Management s Discussion and Analysis of Financial Condition or as described in the other documents and reports we file with the SEC.
Unless the context indicates otherwise, references in this Annual Report on Form 10-K to the Company , Strata , we , us , our , and similar terms refer to Strata Critical Medical, Inc.
Business Business Overview Strata Critical Medical, Inc.(f/k/a Blade Air Mobility, Inc.) ( Strata or the Company ) is a time-critical logistics and medical services provider to the United States healthcare industry.
The Company operates one of the nation s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery.
Strata s core services include air and ground logistics, organ placement, surgical organ recovery, normothermic regional perfusion and preservation for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions ( Trinity ) and Keystone Perfusion Services LLC ( Keystone ) brands.
Strata s mission is to increase the number of organs that are successfully transplanted while leveraging the Company s expertise and resources to provide other medical and logistics services to a broader customer base.
Strata s goals are closely aligned with those of all participants in the transplant ecosystem, including transplant centers, regulators, Organ Procurement Organizations ( OPOs ) and other service providers.
REMOVED
They appear in several places throughout this report and include statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies, the markets in which we operate and the development of Electric Vertical Aircraft ( EVA ) technology.
Unless the context indicates otherwise, references in this Annual Report on Form 10-K to the Company , Blade , we , us , our , and similar terms refer to Blade Air Mobility, Inc.
( Blade or the Company ) provides air transportation and logistics for hospitals across the United States, where it is one of the largest transporters of human organs for transplant, and for passengers, with helicopter and fixed wing services primarily in the Northeast United States and Southern Europe.
Based in New York City, Blade s asset-light model, coupled with its exclusive passenger terminal infrastructure and proprietary technologies, is designed to facilitate a seamless transition from helicopters and fixed-wing aircraft to Electric Vertical Aircraft ( EVA or eVTOL ), enabling lower cost air mobility that is both quiet and emission-free.
Blade currently operates in three key product lines across our Passenger and Medical segments: Passenger segment Short Distance Consisting primarily of helicopter and amphibious seaplane flights in the United States and Europe between 10 and 100 miles in distance.
Flights are available for purchase both by-the-seat and on a full aircraft charter basis.
This product line previously also included flights in Canada, which we discontinued in August 2024.
Jet and Other Consists principally of revenues from non-medical jet charter, revenue from brand partners for exposure to Blade fliers and certain ground transportation services.
This product line previously also included by-the-seat jet flights between New York and South Florida, which we discontinued in November 2023.
Medical segment MediMobility Organ Transport Consisting primarily of transportation of human organs for transplant and/or the medical teams supporting these services.